Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds

Emergent BioSolutions Inc.

Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.
Modification 17 for CYFENDUS anthrax vaccine valued at $30.0M for delivery this year.
Two options totaling $122.9M for VIGIV (smallpox complication) and BAT (botulism antitoxin) into early 2025.
All awards from ASPR under existing 10-year contracts; reaffirms Emergent as trusted biodefense partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.